MIST
What one share of Milestone Pharmaceuticals holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our approved product CARDAMYSTTM (etripamil) nasal spray is available in the United States and is the first and only FDA approved self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs.
Milestone Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.71 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.52 |
| Cash and investments | $1.36 |
| Debt | $0.48 |
| Book value | $0.15 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$3.50 | $0.03 | −$3.27 | — | $4.69 |
| 2020 | — | −$1.70 | — | −$1.73 | — | $4.80 |
| 2021 | — | −$1.02 | — | −$0.79 | — | $3.77 |
| 2022 | — | −$1.38 | $0.01 | −$1.25 | — | $1.94 |
| 2023 | — | −$1.39 | $0.00 | −$1.08 | — | $0.50 |
| 2024 | — | −$0.67 | $0.00 | −$0.47 | — | $0.25 |
| 2025 | — | −$0.75 | $0.00 | −$0.59 | — | $0.39 |